RAMAT GAN, Israel--(BUSINESS WIRE)--LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario™ smartphone-based medical device and diabetes management system, announces its participation in the Rodman & Renshaw 15th Annual Healthcare Conference, to be held September 9-10, 2013 at the Millennium Broadway Hotel in New York City.
Dr. Oren Fuerst, LabStyle’s Executive Chairman, will present a corporate overview on Tuesday, September 10 at 9:10 a.m. Eastern time. The presentation will be webcast live and archived on the company’s website at www.mydario.com.
Dr. Fuerst and Erez Raphael, LabStyle’s President and CEO, will be available for one-on-one meetings with investors who are registered to attend the conference. Institutional investors can register at www.rodm.com and subsequently access the conference website to request a one-on-one meeting.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) is developing and commercializing a patent-pending technology that seeks to bring rapid diagnostic capabilities to consumers in a distinctive and easy-to-use way through the use of smartphones such as iPhones, Androids and other mobile devices. LabStyle’s initial product is Dario™, an integrated medical device and software system addressing the market for diabetic self monitoring of blood glucose (SMBG), a market which is estimated to exceed $10 billion worldwide. Dario is a comprehensive, patent-pending system that combines an all-in-one medical device consisting of an integrated lancet (to obtain a blood sample), a device-specific disposable test strip cartridge and a smartphone-driven glucose reader adaptor, together with a smartphone app and cloud-based data services. LabStyle is pursuing patent applications in multiple jurisdictions covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information, please visit www.mydario.com.
Cautionary Note Regarding Forward-Looking Statements
This news release, the investor presentation referred to herein, and the statements of representatives and partners of LabStyle Innovations Corp. (the Company) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.